{"id":"exenatide-long-acting-release","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL5316203","moleculeType":null,"molecularWeight":"4186.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to and activating the GLP-1 receptor, which stimulates the release of insulin and decreases the release of glucagon. This results in a decrease in blood glucose levels. Additionally, it slows gastric emptying, which also helps to lower blood glucose levels.","oneSentence":"Exenatide, long acting release, works by mimicking the action of a natural hormone in the body to help lower blood sugar levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:53.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00803920","phase":"","title":"Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2006-12","conditions":"Type 2 Diabetes Mellitus","enrollment":8},{"nctId":"NCT00806520","phase":"","title":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00308139","phase":"PHASE3","title":"Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":303},{"nctId":"NCT00641056","phase":"PHASE3","title":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT00637273","phase":"PHASE3","title":"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT00612794","phase":"PHASE1","title":"A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT00103935","phase":"PHASE2","title":"Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-02","conditions":"Type 2 Diabetes Mellitus","enrollment":45}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"GASTROENTERITIS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"BLADDER CANCER"},{"count":1,"reaction":"BLOOD AMYLASE DECREASED"},{"count":1,"reaction":"BLOOD CREATINE PHOSPHOKINASE DECREASED"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"},{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"CELLULITIS"}],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BYDUREON"],"phase":"phase_3","status":"active","brandName":"exenatide, long acting release","genericName":"exenatide, long acting release","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exenatide, long acting release, works by mimicking the action of a natural hormone in the body to help lower blood sugar levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2011-06-17T00:00:00.000Z","mah":"AstraZeneca AB","brand_name_local":"Bydureon","application_number":"EMEA/H/C/002020"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}